Literature DB >> 29153198

N-Terminal B-type Natriuretic Peptide in Heart Failure.

Arthur Mark Richards1.   

Abstract

Plasma amino-terminal pro-B-type natriuretic peptide (NT-proBNP) is a guideline-mandated biomarker in heart failure (HF). Used as an inclusion criterion for therapeutic trials, NT-proBNP enriches trial populations and is a valid surrogate endpoint. Its diagnostic performance is best validated in acute decompensated HF (ADHF). NT-proBNP offers prognostic information independent of standard clinical predictors and refines risk stratification. With the advent of combined angiotensin 2 type 1 receptor blockade and neprilysin inhibition (ARNI) NT-proBNP retains its relationship to cardiac status and is the marker of choice in assessment of possible ADHF and in serial monitoring of HF patients receiving ARNI treatment.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Heart failure; Monitoring; NT-proBNP; Prognosis

Mesh：

Substances：

Year:  2018        PMID： 29153198     DOI： 10.1016/j.hfc.2017.08.004

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN： 1551-7136            Impact factor:   3.179


  13 in total

Review 1.  Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options.

Authors:  Edoardo Gronda; Emilio Vanoli; Stefania Sacchi; Guido Grassi; Giuseppe Ambrosio; Claudio Napoli
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

2.  High-Sensitivity Cardiac Troponin-T and N-Terminal Prohormone of B-Type Natriuretic Peptide in Relation to Cardiovascular Outcomes in Type 1 Diabetes.

Authors:  Tina Costacou; Amy K Saenger; Trevor J Orchard
Journal:  Diabetes Care       Date:  2020-07-02       Impact factor: 19.112

3.  Troponins in Heart Failure - a Perpetual Challenge.

Authors:  Leonida Gherasim
Journal:  Maedica (Buchar)       Date:  2019-12

Review 4.  The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis.

Authors:  Xiaoyu Zheng; Weijin Zheng; Bo Xiong; Jing Huang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

Review 5.  Natriuretic Peptides in Chronic Heart Failure.

Authors:  Hans-Peter Brunner-La Rocca; Sandra Sanders-van Wijk
Journal:  Card Fail Rev       Date:  2019-02

Review 6.  Heart failure with preserved ejection fraction: insights from recent clinical researches.

Authors:  Mi-Na Kim; Seong-Mi Park
Journal:  Korean J Intern Med       Date:  2020-04-29       Impact factor: 2.884

7.  Using Soluble ST2 to Predict Adverse Postoperative Outcomes in Patients with Impaired Left Ventricular Function Undergoing Coronary Bypass Surgery.

Authors:  Ahmet Dolapoglu; Eyup Avci; Tarik Yildirim; Hasan Kadi; Ahmet Celik
Journal:  Medicina (Kaunas)       Date:  2019-09-07       Impact factor: 2.430

Review 8.  Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs.

Authors:  Yei-Tsung Chen; Lee Lee Wong; Oi Wah Liew; Arthur Mark Richards
Journal:  Cells       Date:  2019-12-16       Impact factor: 6.600

9.  Precise safety pharmacology studies of lapatinib for onco-cardiology assessed using in vivo canine models.

Authors:  Kentaro Ando; Takeshi Wada; Xin Cao
Journal:  Sci Rep       Date:  2020-01-20       Impact factor: 4.379

Review 10.  Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop.

Authors:  Sana M Al-Khatib; Emelia J Benjamin; Christine M Albert; Alvaro Alonso; Cynthia Chauhan; Peng-Sheng Chen; Anne B Curtis; Patrice Desvigne-Nickens; Jennifer E Ho; Carolyn S P Lam; Mark S Link; Kristen K Patton; Margaret M Redfield; Michiel Rienstra; Yves Rosenberg; Renate Schnabel; John A Spertus; Lynne Warner Stevenson; Mellanie True Hills; Adriaan A Voors; Lawton S Cooper; Alan S Go
Journal:  Circulation       Date:  2020-06-08       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.